secwatch.observer — SEC 8-K summary
======================================

Issuer:     Owlet, Inc. (OWLT)
CIK:        0001816708
Form:       8-K
Filed at:   2023-11-13T23:59:59+00:00
Accession:  0001628280-23-038605
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Owlet Q3 2023 revenue $9.2M, net loss $5.6M; FDA clears Dream Sock OTC
----------------------------------------------------------------------

- Q3 revenue $9.2M, down 47% YoY due to shift to Amazon first-party seller; sell-in shifted to Q4.
- Net loss narrowed to $5.6M ($0.84/sh) from $19.4M ($2.42/sh) in Q3 2022.
- Gross margin improved to 36.3% from 26.6%; operating expenses cut to $11.2M from $26.4M.
- FDA de novo authorization for Dream Sock as first OTC pulse oximeter for healthy infants; launch by Dec 2023.
- BabySat monitoring system market introduction began; commercial launch target by end of 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1816708/000162828023038605/0001628280-23-038605-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1816708/000162828023038605/owlt-20231113.htm
  HTML page:      https://secwatch.observer/filing/0001628280-23-038605

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer